Judit Herreros Danés
Grau: Doctor/a
973 702 950
judit.herreros(ELIMINAR)@udl.cat
ResearcherID: http://www.researcherid.com/rid/B-5809-2009
Publicacions
-
Bhardwaj, D; Nager, M; Visa, A; Sallan, MC; Coopman, PJ; Canti, C; Herreros, J
Phosphorylated Tyr142 beta-catenin localizes to centrosomes and is regulated by Syk
Journal Of Cellular Biochemistry 119 3632-3640. .
-
Nager, M; Sallan, MC; Visa, A; Pushparaj, C; Santacana, M; Macia, A; Yeramian, A; Canti, C; Herreros, J
Inhibition of WNT-CTNNB1 signaling upregulates SQSTM1 and sensitizes glioblastoma cells to autophagy blockers
Autophagy 14 619-636. .
-
Sallan, MC; Visa, A; Shaikh, S; Nager, M; Herreros, J; Canti, C
T-type Ca2+ Channels: T for Targetable
CANCER RESEARCH 78 603-609. .
-
Barcelo, C; Maiques, O; Panosa, A; Pijuan, J; Orgaz, JL; Vilella, R; Fabra, A; Puig, S; Sanz-Moreno, V; Matias-Guiu, X; Herreros, J; Canti, C; Macia, A; Marti, RM
T-type calcium channel blockers reduce migration/invasion in BRAFV600E melanoma cells by inhibiting autophagy
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY 31 66-66. .
-
Maiques, O; Macia, A; Moreno, S; Barcelo, C; Santacana, M; Vea, A; Herreros, J; Gatius, S; Ortega, E; Valls, J; Chen, BJ; Llobet-Navas, D; Matias-Guiu, X; Canti, C; Marti, RM
Immunohistochemical analysis of T-type calcium channels in acquired melanocytic naevi and melanoma
BRITISH JOURNAL OF DERMATOLOGY 176 1247-1258. .
-
Pushparaj, C; Das, A; Purroy, R; Nàger, M.; Herreros, J; Pamplona, R; Canti, C
Voltage-gated calcium channel blockers deregulate macroautophagyin cardiomyocytes (vol 68, pg 166, 2015)
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY 70 173-173. .
-
Macia, A; Herreros, J; Marti, RM; Canti, C
Calcium Channel Expression and Applicability as Targeted Therapies in Melanoma (vol 2015, 587138, 2015)
BioMed Research International 2016 3017536-3017536. .
-
Nager, M; Santacana, M; Bhardwaj, D; Valls, J; Ferrer, I; Nogues, P; Canti, C; Herreros, J
Nuclear phosphorylated Y142 beta-catenin accumulates in astrocytomas and glioblastomas and regulates cell invasion
CELL CYCLE 14 3644-3655. .
-
Pushparaj C; Das A; Purroy R; Nàger M; Herreros J; Pamplona R; Cantí C
Voltage-gated calcium channel blockers deregulate macroautophagy in cardiomyocytes
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY 68 166-175. .
-
Macia, A.; Herreros, J.; Marti, R. M.; Canti, C.
Calcium Channel Expression and Applicability as Targeted Therapies in Melanoma
BioMed Research International 2015 -. .
-
Cornago M; Garcia-Alberich C; Blasco-Angulo N; Vall-Llaura N; Nager M; Herreros J; Comella JX; Sanchis D; Llovera M
Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe
CELL DEATH & DISEASE 5 -. .
-
Das, Arindam; Pushparaj, Charumathi; Herreros, Judit; Nager, Mireia; Vilella, Ramon; Portero, Manuel; Pamplona, Reinald; Matias-Guiu, Xavier; Marti, Rosa M.; Canti, Carles
T-type calcium channel blockers inhibit autophagy and promote apoptosis of malignant melanoma cells
PIGMENT CELL & MELANOMA RESEARCH 26 874-885. .
Projectes
- Disrupción del contexto protumoral del glioblastoma: modulación de canales iónicos en las distintas poblaciones celulares implicadas
- INVESTIGO 2022: Senyalització cel·lular per calci
- Targeting calcium channels against primary and resistant glioblastoma
- Nuevos mecanismos de desregulación de la señalización por calcio contra el glioblastoma
- POSTDOCTORAL AECC 2017: ESTUDIO DE LA HETEROGENEIDAD TUMORAL EN EL MELANOMA HUMANO. ESTUDIO DE LAS RESISTENCIAS A FARMACOS CONVENCIONALES Y EL PROCESO AUTOFAGICO
- IMPLEMENTATION OF PERSONALIZE MEDICINE IN CUTANEOUS MELANOMA BASED ON GENOMIC SUSCEPTIBILITY AND TUMOR SIGNATURES: IDENTIFICATION OF NEW TARGETS FOR MELANOMA TREATMENT
- Regulación del flujo autofágico en el glioblastoma multiforme: hacia la identificación de nuevas estrategias terapéuticas
- FUNCION DE BETA-CATENINA DURANTE LA DIFERENCIACION NEURONAL Y EN LA INVASIVIDAD DE CELULAS TUMORALES CEREBRALES: PAPEL DE LA FOSFORILACION EN TIROSINA
- Nano-Glio-Blast: mejora de diana cerebral de agentes terapéuticos para el glioblastoma mediantes el uso de la plataforma tecnológica patentada BP-EVs